Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Granules OmniChem is the former name of an India-based pharmaceutical manufacturing company established in 2011 as a joint venture between Granules India and S.A. Ajinomoto OmniChem. The business focused on development and manufacture of small-molecule active pharmaceutical ingredients, intermediates, and pharmaceuticals, serving global biopharma customers from its Visakhapatnam, India site. Ajinomoto agreed in August 2019 to acquire the remaining 50% stake, and Ajinomoto Bio-Pharma Services announced completion of the transaction on June 2, 2020. Following the acquisition, the business began operating as Ajinomoto Bio-Pharma Services India and became integrated into Ajinomoto Bio-Pharma Services' global CDMO network. For biotech and pharma analysts, Granules OmniChem is best understood as a historical company name for a now wholly owned Ajinomoto small-molecule CDMO/manufacturing site in India.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Granules OmniChem.